文献速递精神分裂症与精神病性障碍物质与行为成瘾

持续使用大麻与首发精神病患者药物依从性差及复发风险的关系:一项前瞻性分析

Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis.
PubMed 文献 · Lancet Psychiatry · 2017-07-10

该前瞻性分析纳入245例首发精神病患者,随访2年,发现持续使用大麻可预测复发风险、复发次数、复发持续时间及护理强度增加。结构方程模型显示,药物依从性部分中介了大麻使用对复发风险等结局的影响,中介比例为20%至36%。

要点

  • 持续使用大麻与首发精神病患者复发风险增加相关,药物依从性差是部分中介因素。
  • 中介分析显示,药物依从性对复发风险的中介比例为26%,对复发次数为36%。
  • 针对药物依从性的干预可能部分减轻大麻使用对精神病结局的危害。

核心结论

  • 持续使用大麻对精神病结局的不良影响中,约20%至36%可能通过药物依从性中介。
  • 针对药物依从性的干预可能部分减轻大麻使用对精神病患者的危害。

研究设计与样本

  • 前瞻性分析,纳入英国伦敦South London and Maudsley NHS Foundation Trust四个成人住院和门诊单位的245例首发精神病患者,随访2年。
  • 大麻使用通过面对面随访自报评估,复发数据来自临床记录(WHO Life Chart Schedule),药物依从性基于访谈和临床记录评估。
  • 采用结构方程模型分析药物依从性是否部分中介持续大麻使用对复发风险的影响。

主要发现

  • 245例首发精神病患者中,91例(37%)在2年随访期内复发。
  • 持续使用大麻预测不良结局,包括复发风险、复发次数、复发持续时间和随访时护理强度。

关键数值与推荐

  • 复发定义为首次就诊精神科服务后2年内症状加重导致入住精神科住院单元。
  • 纳入标准为符合ICD-10诊断标准的首发非器质性或情感性精神病,转诊至当地精神科服务时年龄18至65岁。

临床怎么用

  • 对首发精神病患者应评估大麻使用情况,并针对药物依从性进行干预,可能部分减轻大麻相关危害。

局限性

  • 397例患者中133例拒绝参与,19例因数据缺失未纳入,可能引入选择偏倚。
  • 大麻使用基于自报,可能存在报告偏倚。
  • 研究为观察性分析,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cannabis use following the onset of first-episode psychosis has been linked to both increased risk of relapse and non-adherence with antipsychotic medication. Whether poor outcome associated with cannabis use is mediated through an adverse effect of cannabis on medication adherence is unclear. METHODS: In a prospective analysis of data acquired from four different adult inpatient and outpatient units of the South London and Maudsley Mental Health National Health Service Foundation Trust in London, UK, 245 patients were followed up for 2 years from the onset of first-episode psychosis. Cannabis use after onset of psychosis was assessed by self-reports in face-to-face follow-up interviews. Relapse data were collected from clinical notes using the WHO Life Chart Schedule. This measure was also used to assess medication adherence on the basis of both face-to-face interviews and clinical notes. Patients were included if they had a diagnosis of first-episode non-organic or affective psychosis according to ICD-10 criteria, and were aged between 18 and 65 years when referred to local psychiatric services. We used structural equation modelling analysis to estimate whether medication adherence partly mediated the effects of continued cannabis use on risk of relapse. The primary outcome variable was relapse, defined as admission to a psychiatric inpatient unit after exacerbation of symptoms within 2 years of first presentation to psychiatric services. Information on cannabis use over the first 2 years after onset of psychosis was investigated as a predictor variable for relapse. Medication adherence was assessed as a mediator variable on the basis of clinical records and self-report data. Study researchers (TS, NP, EK, and EF) rated the adherence. FINDINGS: 397 patients who presented with their first episode of psychosis between April 12, 2002, and July 26, 2013 had a follow-up assessment until September, 2015. Of the 397 patients approached for followed up, 133 refused to take part in this study and 19 could not be included because of missing data. 91 (37%) of 245 patients with first-episode psychosis had a relapse over the 2 years of follow-up. Continued cannabis use predicted poor outcome, including risk of relapse, number of relapses, length of relapse, and care intensity at follow-up. In controlled structural equation modelling analyses, medication adherence partly mediated the effect of continued cannabis use on outcome, including risk of relapse (proportion mediated=26%, βindirect effects=0·08, 95% CI 0·004 to 0·16), number of relapses (36%, βindirect effects=0·07, 0·003 to 0·14), time until relapse (28%, βindirect effects=-0·26, -0·53 to 0·001) and care intensity (20%, βindirect effects=0·06, 0·004 to 0·11) but not length of relapse (6%, βindirect effects=0·03, -0·03 to 0·09). The adjusted models explained moderate amounts of variance for outcomes defined as risk of relapse (R2=0·25), number of relapses (R2=0·21), length of relapse (R2=0·07), time until relapse (R2=0·08), and care intensity index (R2=0·15). INTERPRETATION: Between 20% and 36% of the adverse effects of continued cannabis use on outcome in psychosis might be mediated through the effects of cannabis use on medication adherence. Interventions directed at medication adherence could partly help mitigate the harm from cannabis use in psychosis. FUNDING: This study is funded by the National Institute of Health Research (NIHR) Clinician Scientist award.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Schoeler T, Petros N, Di Forti M, et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017. PMID: 28705600. doi:10.1016/S2215-0366(17)30233-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。